Both Ibrutinib and Idelalisib have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.
Source: Reuters, 25/07/14.
Great news but more work to be done here in the UK to gain approval for the Cancer Drugs Fund and NICE.
Watch this space.